Clinical characteristics and current treatment of age-related macular degeneration

Cold Spring Harbor Perspectives in Medicine

Volumn 5, Issue 1, 2015, Pages

  Yonekawa, Yoshihiro ^a   Kim, Ivana K ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; ALPHA TOCOPHEROL; ASCORBIC ACID; BETA CAROTENE; BEVACIZUMAB; COPPER; DOCOSAHEXANOIC ACID; EICOSAPENTANOIC ACID; INFLAMMASOME; LAMPALIZUMAB; LIPOFUSCIN; OMEGA 3 FATTY ACID; PEGAPTANIB; PLACEBO; RANIBIZUMAB; UNCLASSIFIED DRUG; VERTEPORFIN; XANTHOPHYLL; ZEAXANTHIN; ZINC OXIDE; ANGIOGENESIS INHIBITOR; APTAMER; HYBRID PROTEIN; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR;

AGE; AGE RELATED MACULAR DEGENERATION; AGING; ARTICLE; CARDIOVASCULAR DISEASE; CAROTID ATHEROSCLEROSIS; GEOGRAPHIC ATROPHY; HUMAN; LASER COAGULATION; MACULAR DEGENERATION; MINERAL SUPPLEMENTATION; NEOVASCULAR AGE RELATED MACULAR DEGENERATION; NEUROPROTECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTODYNAMIC THERAPY; PHOTORECEPTOR; PIGMENT EPITHELIUM; POLYPOIDAL CHOROIDAL VASCULOPATHY; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETICULAR PSEUDODRUSEN; RETINA MACULA TRANSLOCATION; RETINAL ANGIOMATOUS PROLIFERATION; SMOKING; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; SUBRETINAL FLUID; SUBRETINAL NEOVASCULARIZATION; AGED; ANTAGONISTS AND INHIBITORS; DRUG COMBINATION; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHOTOCHEMOTHERAPY; PROCEDURES; RISK FACTOR;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; APTAMERS, NUCLEOTIDE; COMBINED MODALITY THERAPY; DRUG THERAPY, COMBINATION; HUMANS; LIGHT COAGULATION; MACULAR DEGENERATION; MIDDLE AGED; PHOTOCHEMOTHERAPY; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RISK FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84923819247     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a017178     Document Type: Article

References (122)

1. AREDS Study Group. 2000. Risk factors associated with age-related macular degeneration. A case-control study in the age-related eye disease study: Age-Related Eye Disease Study Report Number 3. Ophthalmology 107: 2224-2232.
2. AREDS Study Group. 2001. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, b carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 119: 1417-1436.
3. AREDS2 Study Group. 2013. Lutein þ zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA 309: 2005-2015.
4. Arnold JJ, Sarks SH, Killingsworth MC, Sarks JP. 1995. Reticular pseudodrusen. A risk factor in age-related maculopathy. Retina 15: 183-191.
5. Blumenkranz MS, Bressler NM, Bressler SB, Donati G, Fish GE, Haynes LA, Lewis H, Miller JW, Mones JM, Potter MJ, et al. 2002. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: Three-year results of an open-label extension of 2 randomized clinical trials-TAP Report no. 5. Arch Ophthalmol 120: 1307-1314.
6. Boyer D. 2013. A phase 2b study of Fovista TM, a platelet derived growth factor (PDGF) inhibitor in combination with a vascular endothelial growth factor (VEGF) inhibitor for neovascular age-related macular degeneration (AMD). Association for Research in Vision and Ophthalmology Annual Meeting, Abstract 2175. Seattle, May 5-9.
7. Bressler NM, TAP Study Group. 2001. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: Two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol 119: 198-207.
8. Bressler NM, Silva JC, Bressler SB, Fine SL, Green WR. 1994. Clinicopathologic correlation of drusen and retinal pigment epithelial abnormalities in age-related macular degeneration. Retina 14: 130-142.
9. Bressler NM, Bressler SB, Childs AL, Haller JA, Hawkins BS, Lewis H, MacCumber MW, Marsh MJ, Redford M, Sternberg P Jr, et al. 2004. Surgery for hemorrhagic choroidal neovascular lesions of age-related macular degeneration: Ophthalmic findings: SST report no. 13. Ophthalmology 111: 1993-2006.
10. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T. 2009. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology 116: 57-65, e55.
11. Browning DJ, Kaiser PK, Rosenfeld PJ, Stewart MW. 2012. Aflibercept for age-related macular degeneration: A game-changer or quiet addition? Am J Ophthalmol 154: 222-226.
12. Campochiaro PA, Channa R, Berger BB, Heier JS, Brown DM, Fiedler U, Hepp J, Stumpp MT. 2013. Treatment of diabetic macular edema with a designed ankyrin repeat protein that binds vascular endothelial growth factor: A phase I/II study. Am J Ophthalmol 155: 697-704, 704 e691-e692.
13. Childs AL, Bressler NM, Bass EB, Hawkins BS, Mangione CM, Marsh MJ, Miskala PH. 2004. Surgery for hemorrhagic choroidal neovascular lesions of age-related macular degeneration: Quality-of-life findings: SST report no. 14. Ophthalmology 111: 2007-2014.
14. Christen WG, Glynn RJ, Manson JE, Ajani UA, Buring JE. 1996. A prospective study of cigarette smoking and risk of age-related macular degeneration in men. JAMA 276: 1147-1151.
15. Cohen SY, Dubois L, Tadayoni R, Delahaye-Mazza C, Debibie C, Quentel G. 2007. Prevalence of reticular pseudodrusen in age-related macular degeneration with newly diagnosed choroidal neovascularisation. Br J Ophthalmol 91: 354-359.
16. Cukras C, Agron E, Klein ML, Ferris FL 3rd, Chew EY, Gensler G, Wong WT. 2010. Natural history of drusenoid pigment epithelial detachment in age-related macular degeneration: Age-Related Eye Disease Study Report No. 28. Ophthalmology 117: 489-499.
17. Curcio CA, Millican CL, Allen KA, Kalina RE. 1993. Aging of the human photoreceptor mosaic: Evidence for selective vulnerability of rods in central retina. Invest Ophthalmol Vis Sci 34: 3278-3296.
18. Daneshvar H, Kertes PJ, Leonard BC, Peyman GA. 1999. Management of submacular hemorrhage with intravitreal sulfur hexafluoride: A pilot study. Can J Ophthalmol 34: 385-388.
19. de Juan E Jr, Loewenstein A, Bressler NM, Alexander J. 1998. Translocation of the retina for management of subfoveal choroidal neovascularization II: A preliminary report in humans. Am J Ophthalmol 125: 635-646.
20. Do DV, Gower EW, Cassard SD, Boyer D, Bressler NM, Bressler SB, Heier JS, Jefferys JL, Singerman LJ, Solomon SD. 2012. Detection of new-onset choroidal neovascularization using optical coherence tomography: The AMD DOC Study. Ophthalmology 119: 771-778.
21. Doyle SL, Campbell M, Ozaki E, Salomon RG, Mori A, Kenna PF, Farrar GJ, Kiang AS, Humphries MM, Lavelle EC, et al. 2012. NLRP3 has a protective role in age-related macular degeneration through the induction of IL-18 by drusen components. Nat Med 18: 791-798.
22. Eye-Disease-Case-Control-Study-Group. 1992. Risk factors for neovascular age-related macular degeneration. Arch Ophthalmol 110: 1701-1708.
23. Feehan M, Hartman J, Durante R, Morrison MA, Miller JW, Kim IK, DeAngelis MM. 2011. Identifying subtypes of patients with neovascular age-related macular degeneration by genotypic and cardiovascular risk characteristics. BMC Med Genet 12: 83.
24. Feeney-Burns L, Berman ER, Rothman H. 1980. Lipofuscin of human retinal pigment epithelium. Am J Ophthalmol 90: 783-791.
25. Feeney-Burns L, Burns RP, Gao CL. 1990. Age-related macular changes in humans over 90 years old. Am J Ophthalmol 109: 265-278.
26. Ferris FL III, Fine SL, Hyman L. 1984. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 102: 1640-1642.
27. Freund KB, Ho IV, Barbazetto IA, Koizumi H, Laud K, Ferrara D, Matsumoto Y, Sorenson JA, Yannuzzi L. 2008. Type 3 neovascularization: The expanded spectrum of retinal angiomatous proliferation. Retina 28: 201-211.
28. Friedman DS, O’Colmain BJ, Munoz B, Tomany SC, McCarty C, de Jong PT, Nemesure B, Mitchell P, Kempen J. 2004. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 122: 564-572.
29. Garcia Filho CA, Yehoshua Z, Gregori G, Nunes RP, Penha FM, Moshfeghi AA, Zhang K, Feuer W, Rosenfeld PJ. 2014. Change in drusen volume as a novel clinical trial endpoint for the study of complement inhibition in age- related macular degeneration. Ophthalmic Surg Lasers Imaging Retina 45: 18-31.
30. Gass JD, Agarwal A, Lavina AM, Tawansy KA. 2003. Focal inner retinal hemorrhages in patients with drusen: An early sign of occult choroidal neovascularization and chorioretinal anastomosis. Retina 23: 741-751.
31. Goldberg J, Flowerdew G, Smith E, Brody JA, Tso MO. 1988. Factors associated with age-related macular degeneration. An analysis of data from the first National Health and Nutrition Examination Survey. Am J Epidemiol 128: 700-710.
32. Gomi F, Sawa M, Sakaguchi H, Tsujikawa M, Oshima Y, Kamei M, Tano Y. 2008. Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy. Br J Ophthalmol 92: 70-73.
33. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. 2004. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351: 2805-2816.
34. Hartnett ME, Weiter JJ, Garsd A, Jalkh AE. 1992. Classification of retinal pigment epithelial detachments associated with drusen. Graefes Arch Clin Exp Ophthalmol 230: 11-19.
35. Hassan AS, Johnson MW, Schneiderman TE, Regillo CD, Tornambe PE, Poliner LS, Blodi BA, Elner SG. 1999. Management of submacular hemorrhage with intravitreous tissue plasminogen activator injection and pneumatic displacement. Ophthalmology 106: 1900-1907.
36. Hattenbach LO, Klais C, Koch FH, Gumbel HO. 2001. Intravitreous injection of tissue plasminogen activator and gas in the treatment of submacular hemorrhage under various conditions. Ophthalmology 108: 1485-1492.
37. Haupert CL, McCuen BW II, Jaffe GJ, Steuer ER, Cox TA, Toth CA, Fekrat S, Postel EA. 2001. Pars plana vitrectomy, subretinal injection of tissue plasminogen activator, and fluid-gas exchange for displacement of thick submacular hemorrhage in age-related macular degeneration. Am J Ophthalmol 131: 208-215.
38. Hawkins BS, Bressler NM, Miskala PH, Bressler SB, Holekamp NM, Marsh MJ, Redford M, Schwartz SD, Sternberg P Jr, Thomas MA, et al. 2004. Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: Ophthalmic findings: SSTreport no. 11. Ophthalmology 111: 1967-1980.
39. Heier JS, Brown DM, Chong V, Korobelnik J-F, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Yancopoulos GD, et al. 2012. Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration. Ophthalmology 119: 2537-2548.
40. Holz FG, Bellman C, Staudt S, Schutt F, Volcker HE. 2001. Fundus autofluorescence and development of geographic atrophy in age-related macular degeneration. Invest Ophthalmol Vis Sci 42: 1051-1056.
41. Hyman L, Schachat AP, He Q, Leske MC. 2000. Hypertension, cardiovascular disease, and age-related macular degeneration. Age-Related Macular Degeneration Risk Factors Study Group. Arch Ophthalmol 118: 351-358.
42. Imamura Y, Engelbert M, Iida T, Freund KB, Yannuzzi LA. 2010. Polypoidal choroidal vasculopathy: A review. Surv Ophthalmol 55: 501-515.
43. Kaiser PK. 2009. Verteporfin PDT for subfoveal occult CNV in AMD: Two-year results of a randomized trial. Curr Med Res Opin 25: 1853-1860.
44. Kaiser PK, Boyer DS, Cruess AF, Slakter JS, Pilz S, Weisberger A. 2012. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: Twelve-month results of the DENALI study. Ophthalmology 119: 1001-1010.
45. Kang HM, Kim YM, Koh HJ. 2013. Five-year follow-up results of photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol 155: 438-447, e431.
46. Kawasaki R, Yasuda M, Song SJ, Chen SJ, Jonas JB, Wang JJ, Mitchell P, Wong TY. 2010. The prevalence of age-related macular degeneration in Asians: A systematic review and meta-analysis. Ophthalmology 117: 921-927.
47. Khurana RN, Dupas B, Bressler NM. 2010. Agreement of time-domain and spectral-domain optical coherence tomography with fluorescein leakage from choroidal neovascularization. Ophthalmology 117: 1376-1380.
48. Kim SJ, Yu HG. 2011. Efficacy of combined photodynamic therapy and intravitreal bevacizumab injection versus photodynamic therapy alone in polypoidal choroidal vasculopathy. Retina 31: 1827-1834.
49. Klein R, Klein BE, Linton KL. 1992. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology 99: 933-943.
50. Klein R, Klein BE, Franke T. 1993. The relationship of cardiovascular disease and its risk factors to age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology 100: 406-414.
51. Klein R, Klein BE, Tomany SC, Cruickshanks KJ. 2003. The association of cardiovascular disease with the long-term incidence of age-related maculopathy: The Beaver Dam Eye Study. Ophthalmology 110: 1273-1280.
52. Klein ML, Ferris FL III, Armstrong J, Hwang TS, Chew EY, Bressler SB, Chandra SR. 2008a. Retinal precursors and the development of geographic atrophy in age-related macular degeneration. Ophthalmology 115: 1026-1031.
53. Klein R, Meuer SM, Knudtson MD, Iyengar SK, Klein BE. 2008b. The epidemiology of retinal reticular drusen. Am J Ophthalmol 145: 317-326.
54. Klein R, Cruickshanks KJ, Myers CE, Sivakumaran TA, Iyengar SK, Meuer SM, Schubert CR, Gangnon RE, Klein BE. 2013. The relationship of atherosclerosis to the 10-year cumulative incidence of age-related macular degeneration: The Beaver Dam studies. Ophthalmology 120: 1012-1019.
55. Koh A, Lee WK, Chen LJ, Chen SJ, Hashad Y, Kim H, Lai TY, Pilz S, Ruamviboonsuk P, Tokaji E, et al. 2012. EVEREST study: Efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina 32: 1453-1464.
56. Koizumi H, Yamagishi T, Yamazaki T, Kinoshita S. 2011. Predictive factors of resolved retinal fluid after intravitreal ranibizumab for polypoidal choroidal vasculopathy. Br J Ophthalmol 95: 1555-1559.
57. Kubota R, Boman NL, David R, Mallikaarjun S, Patil S, Birch D. 2012. Safety and effect on rod function of ACU-4429, a novel small-molecule visual cycle modulator. Retina 32: 183-188.
58. Kurashige Y, Otani A, Sasahara M, Yodoi Y, Tamura H, Tsujikawa A, Yoshimura N. 2008. Two-year results of photo- dynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol 146: 513-519.
59. Laatikainen L, Larinkari J. 1977. Capillary-free area of the fovea with advancing age. Invest Ophthalmol Vis Sci 16: 1154-1157.
60. Lai JC, Lapolice DJ, Stinnett SS, Meyer CH, Arieu LM, Keller MA, Toth CA. 2002. Visual outcomes following macular translocation with 360-degree peripheral retinectomy. Arch Ophthalmol 120: 1317-1324.
61. Larsen M, Schmidt-Erfurth U, Lanzetta P, Wolf S, Simader C, Tokaji E, Pilz S, Weisberger A. 2012. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: Twelve-month MONT BLANC study results. Ophthalmology 119: 992-1000.
62. Lee SY, Stetson PF, Ruiz-Garcia H, Heussen FM, Sadda SR. 2012a. Automated characterization of pigment epithelial detachment by optical coherence tomography. Invest Ophthalmol Vis Sci 53: 164-170.
63. Lee YA, Yang CH, Yang CM, Ho TC, Lin CP, Huang JS, Chen MS. 2012b. Photodynamic therapy with or without intravitreal bevacizumab for polypoidal choroidal vasculopathy: Two years of follow-up. Am J Ophthalmol 154: 872-880, e872.
64. Lukason M, DuFresne E, Rubin H, Pechan P, Li Q, Kim I, Kiss S, Flaxel C, Collins M, Miller J, et al. 2011. Inhibition of choroidal neovascularization in a nonhuman primate model by intravitreal administration of an AAV2 vector expressing a novel anti-VEGF molecule. Mol Ther 19: 260-265.
65. Machemer R, Steinhorst UH. 1993. Retinal separation, retinotomy, and macular relocation: II. A surgical approach for age-related macular degeneration? Graefes Arch Clin Exp Ophthalmol 231: 635-641.
66. Malamos P, Sacu S, Georgopoulos M, Kiss C, Pruente C, Schmidt-Erfurth U. 2009. Correlation of high-definition optical coherence tomography and fluorescein angiography imaging in neovascular macular degeneration. Invest Ophthalmol Vis Sci 50: 4926-4933.
67. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. 2011. Ranibizumab and bevacizumab for neo- vascular age-related macular degeneration. N Engl J Med 364: 1897-1908.
68. Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL III. 2012. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: Two-year results. Ophthalmology 119: 1388-1398.
69. Maruko I, Iida T, Saito M, Nagayama D, Saito K. 2007. Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol 144: 15-22.
70. Mata NL, Lichter JB, Vogel R, Han Y, Bui TV, Singerman LJ. 2013. Investigation of oral fenretinide for treatment of geographic atrophy in age-related macular degeneration. Retina 33: 498-507.
71. Miller JW. 2013. Age-related macular degeneration revisited-Piecing the puzzle: The LXIX Edward Jackson memorial lecture. Am J Ophthalmol 155: 1-35, e13.
72. Mimoun G, Soubrane G, Coscas G. 1990. Macular drusen. J Fr Ophtalmol 13: 511-530.
73. Mizutani T, Yasukawa T, Ito Y, Takase A, Hirano Y, Yoshida M, Ogura Y. 2011. Pneumatic displacement of submacular hemorrhage with or without tissue plasminogen activator. Graefes Arch Clin Exp Ophthalmol 249: 1153-1157.
74. MPS Study Group. 1982. Argon laser photocoagulation for senile macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol 100: 912-918.
75. MPS Study Group. 1986. Argon laser photocoagulation for neovascular maculopathy. Three-year results from randomized clinical trials. Arch Ophthalmol 104: 694-701.
76. Mruthyunjaya P, Stinnett SS, Toth CA. 2004. Change in visual function after macular translocation with 360˚ retinectomy for neovascular age-related macular degeneration. Ophthalmology 111: 1715-1724.
77. Ninomiya Y, Lewis JM, Hasegawa T, Tano Y. 1996. Retinotomy and foveal translocation for surgical management of subfoveal choroidal neovascular membranes. Am J Ophthalmol 122: 613-621.
78. Ohji M, Saito Y, Hayashi A, Lewis JM, Tano Y. 1998. Pneumatic displacement of subretinal hemorrhage without tissue plasminogen activator. Arch Ophthalmol 116: 1326-1332.
79. Olivier S, Chow DR, Packo KH, MacCumber MW, Awh CC. 2004. Subretinal recombinant tissue plasminogen activator injection and pneumatic displacement of thick submacular hemorrhage in age-related macular degeneration. Ophthalmology 111: 1201-1208.
80. Panda-Jonas S, Jonas JB, Jakobczyk-Zmija M. 1996. Retinal pigment epithelial cell count, distribution, and correlations in normal human eyes. Am J Ophthalmol 121: 181-189.
81. Papadopoulos N, Martin J, Ruan Q, Rafique A, Rosconi MP, Shi E, Pyles EA, Yancopoulos GD, Stahl N, Wiegand SJ. 2012. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 15: 171-185.
82. Pumariega NM, Smith RT, Sohrab MA, Letien V, Souied EH. 2011. A prospective study of reticular macular disease. Ophthalmology 118: 1619-1625.
83. Regillo CD. 2013. Lampalizumab (anti-factor D) in patients with geography atrophy: The MAHALO phase 2 results. Annual Meeting of the American Academy of Ophthalmology, New Orleans, November 16-19.
84. Ron Y, Ehrlich R, Axer-Siegel R, Rosenblatt I, Weinberger D. 2007. Pneumatic displacement of submacular hemorrhage due to age-related macular degeneration. Ophthalmologica 221: 57-61.
85. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY. 2006. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355: 1419-1431.
86. Sarks SH. 1976. Ageing and degeneration in the macular region: a clinico-pathological study. Br J Ophthalmol 60: 324-341.
87. Sarks SH, Van Driel D, Maxwell L, Killingsworth M. 1980. Softening of drusen and subretinal neovascularization. Trans Ophthalmol Soc U K 100: 414-422.
88. Sarks JP, Sarks SH, Killingsworth MC. 1988. Evolution of geographic atrophy of the retinal pigment epithelium. Eye (Lond) 2 (Part 5): 552-577.
89. Sarks S, Cherepanoff S, Killingsworth M, Sarks J. 2007. Relationship of Basal laminar deposit and membranous debris to the clinical presentation of early age-related macular degeneration. Invest Ophthalmol Vis Sci 48: 968-977.
90. Sayanagi K, Sharma S, Yamamoto T, Kaiser PK. 2009. Comparison of spectral-domain versus time-domain optical coherence tomography in management of age-related macular degeneration with ranibizumab. Ophthalmology 116: 947-955.
91. Schmitz-Valckenberg S, Bindewald-Wittich A, Dolar-Szczasny J, Dreyhaupt J, Wolf S, Scholl HP, Holz FG. 2006. Correlation between the area of increased auto- fluorescence surrounding geographic atrophy and disease progression in patients with AMD. Invest Ophthalmol Vis Sci 47: 2648-2654.
92. Schmitz-Valckenberg S, Fleckenstein M, Scholl HP, Holz FG. 2009. Fundus autofluorescence and progression of age- related macular degeneration. Surv Ophthalmol 54: 96-117.
93. Schmitz-Valckenberg S, Steinberg JS, Fleckenstein M, Visvalingam S, Brinkmann CK, Holz FG. 2010. Combined confocal scanning laser ophthalmoscopy and spectral- domain optical coherence tomography imaging of reticular drusen associated with age-related macular degeneration. Ophthalmology 117: 1169-1176.
94. Schwartz SD, Hubschman JP, Heilwell G, Franco-Cardenas V, Pan CK, Ostrick RM, Mickunas E, Gay R, Klimanskaya I, Lanza R. 2012. Embryonic stem cell trials for macular degeneration: a preliminary report. Lancet 379: 713-720.
95. Scott AW, Bressler SB. 2010. Retinal angiomatous proliferation or retinal anastomosis to the lesion. Eye (Lond) 24: 491-496.
96. Seddon JM, Willett WC, Speizer FE, Hankinson SE. 1996. A prospective study of cigarette smoking and age-related macular degeneration in women. JAMA 276: 1141-1146.
97. Singh RP, Patel C, Sears JE. 2006. Management of subretinal macular haemorrhage by direct administration of tissue plasminogen activator. Br J Ophthalmol 90: 429-431.
98. Sommer A, Tielsch JM, Katz J, Quigley HA, Gottsch JD, Javitt JC, Martone JF, Royall RM, Witt KA, Ezrine S. 1991. Racial differences in the cause-specific prevalence of blindness in East Baltimore. N Engl J Med 325: 1412-1417.
99. Sperduto RD, Hiller R. 1986. Systemic hypertension and age-related maculopathy in the Framingham Study. Arch Ophthalmol 104: 216-219.
100. Stewart MW. 2012. Aflibercept (VEGF Trap-eye): The newest anti-VEGF drug. Br J Ophthalmol 96: 1157-1158.
101. TAP Study Group. 1999. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: One-year results of 2 randomized clinical trials-TAP report. Arch Ophthalmol 117: 1329-1345.
102. Tarallo V, Hirano Y, Gelfand BD, Dridi S, Kerur N, Kim Y, Cho WG, Kaneko H, Fowler BJ, Bogdanovich S, et al. 2012. DICER1 loss and Alu RNA induce age-related macular degeneration via the NLRP3 inflammasome and MyD88. Cell 149: 847-859.
103. Tomita K, Tsujikawa A, Yamashiro K, Ooto S, Tamura H, Otani A, Nakayama Y, Yoshimura N. 2012. Treatment of polypoidal choroidal vasculopathy with photodynamic therapy combined with intravitreal injections of ranibizumab. Am J Ophthalmol 153: 68-80, e61.
104. Trichonas G, Murakami Y, Thanos A, Morizane Y, Kayama M, Debouck CM, Hisatomi T, Miller JW, Vavvas DG. 2010. Receptor interacting protein kinases mediate retinal detachment-induced photoreceptor necrosis and compensate for inhibition of apoptosis. Proc Natl Acad Sci 107: 21695-21700.
105. Tsai JC. 2013. Canadian Journal of Ophthalmology Lecture: Translational research advances in glaucoma neuroprotection. Can J Ophthalmol 48: 141-145.
106. van Leeuwen R, Ikram MK, Vingerling JR, Witteman JC, Hofman A, de Jong PT. 2003. Blood pressure, atherosclerosis, and the incidence of age-related maculopathy: The Rotterdam Study. Invest Ophthalmol Vis Sci 44: 3771-3777.
107. Varma R, Fraser-Bell S, Tan S, Klein R, Azen SP. 2004. Prevalence of age-related macular degeneration in Latinos: the Los Angeles Latino eye study. Ophthalmology 111: 1288-1297.
108. Vinding T. 1995. Age-related macular degeneration. An epidemiological study of 1000 elderly individuals. With reference to prevalence, funduscopic findings, visual impairment and risk factors. Acta Ophthalmol Scand Suppl: 1-32.
109. Vingerling JR, Dielemans I, Bots ML, Hofman A, Grobbee DE, de Jong PT. 1995. Age-related macular degeneration is associated with atherosclerosis. The Rotterdam Study. Am J Epidemiol 142: 404-409.
110. VIP Study Group. 2001. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: Two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-Verteporfin in photodynamic therapy report 2. Am J Ophthalmol 131: 541-560.
111. WHO. 2013. Prevention of blindness and visual impairment; priority eye diseases (http://www.who.int/blindness/causes/priority/en/index7.html).
112. Wolff B, Matet A, Vasseur V, Sahel JA, Mauget-Faysse M. 2012. En face OCT imaging for the diagnosis of outer retinal tubulations in age-related macular degeneration. J Ophthalmol 2012: 542417.
113. Wong WT, Kam W, Cunningham D, Harrington M, Hammel K, Meyerle CB, Cukras C, Chew EY, Sadda SR, Ferris FL. 2010. Treatment of geographic atrophy by the topical administration of OT-551: Results of a phase II clinical trial. Invest Ophthalmol Vis Sci 51: 6131-6139.
114. Yamashita A, Shiraga F, Shiragami C, Shirakata Y, Fujiwara A. 2013. Two-year results of reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol 155: 96-102, e101.
115. Yannuzzi LA, Negrao S, Iida T, Carvalho C, Rodriguez-Coleman H, Slakter J, Freund KB, Sorenson J, Orlock D, Borodoker N. 2001. Retinal angiomatous proliferation in age-related macular degeneration. Retina 21: 416-434.
116. Yehoshua Z, de Amorim Garcia Filho CA, Nunes RP, Gregori G, Penha FM, Moshfeghi AA, Zhang K, Sadda S, Feuer W, Rosenfeld PJ. 2014. Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: The COMPLETE study. Ophthalmology 121: 693-701.
117. Yonekawa Y. 2013. Aflibercept for the treatment of refractory polypoidal choroidal vasculopathy. Can J Ophthalmol 48: e59-e60.
118. Zarbin MA. 2004. Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol 122: 598-614.
119. Zhang K, Hopkins JJ, Heier JS, Birch DG, Halperin LS, Albini TA, Brown DM, Jaffe GJ, Tao W, Williams GA. 2011a. Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration. Proc Natl Acad Sci 108: 6241-6245.
120. Zhang M, Zhang J, Yan M, Luo D, Zhu W, Kaiser PK, Yu DC. 2011b. A phase 1 study of KH902, a vascular endothelial growth factor receptor decoy, for exudative age-related macular degeneration. Ophthalmology 118: 672-678.
121. Zweifel SA, Engelbert M, Laud K, Margolis R, Spaide RF, Freund KB. 2009. Outer retinal tubulation: A novel optical coherence tomography finding. Arch Ophthalmol 127: 1596-1602.
122. Zweifel SA, Imamura Y, Spaide TC, Fujiwara T, Spaide RF. 2010. Prevalence and significance of subretinal drusenoid deposits (reticular pseudodrusen) in age-related macular degeneration. Ophthalmology 117: 1775-1781.